COVAX to Buy 380 Million Doses of CoronaVac Vaccine

SINOVAC Biotech Ltd. announced today that it had signed an advance purchase agreement with Gavi, the Vaccine Alliance, on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac for distribution through the COVAX Facility.

Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC, said in a press statement issued on July 12, 2021, “Our mission at Sinovac is to supply vaccines to eliminate human disease. We appreciate the efforts from international organizations, including WHO and COVAX partners, to accelerate the efforts of disease prevention."

"Sinovac has delivered over one billion doses globally as of the end of June 2021 with the aim of contributing to the accessibility and affordability of Covid-19 vaccines during this pandemic. Further, safety and regular transportation and storage condition of inactivated vaccine supports easy access to the vaccine in every corner on the globe.”

The WHO's Strategic Advisory Group of Experts on Immunization (SAGE) had systematically reviewed and evaluated evidence of vaccine safety and effect of Sinovac’s CoronaVac vaccine, recommending two doses of CoronaVac® for adults aged 18 and above. Following the review by SAGE, the WHO announced its intention to authorize Sinovac’s CoronaVac for Emergency Use on June 1, 2021.